TORONTO, Aug. 16, 2024 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventu
The patent application was purchased for consideration of 1,000,000 common shares of Lifeist. In addition, in the event the patent is issued (the “Issued Patent”), Lifeist or 4871 is required to pay to the vendor of 4871 50% of all net revenue generated from the Issued Patent up to a maximum amount of CDN$1,000,000 and in the event a of a sale, assignment, transfer or other disposition of the Issued Patent during the term of the Issued Patent (the “Issued Patent Sale”), Lifeist or 4871 is required to remit 50% of the consideration received on closing of such sale as well any deferred consideration once paid, up to a maximum, in the aggregate, of CDN$1,000,000. Read More
